Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

in uterine serous carcinoma and serous ovarian carcinoma but not in nonserous uterine cancer or benign conditions. "The ...

In view of the possibility that the ovarian mass was a carcinoma, however ... together with free serous fluid in the cul-de-sac. Samples of peritoneal fluid were collected and sent for ...

Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Financially, VSTM has limited cash reserves ...

to characterize chemotherapy resistance mechanisms in ovarian high grade serous carcinoma. The ultimate goal of our cross-disciplinary research is to translate these multi-modal data into testable ...

Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...